CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
40 million people live with HIV globally, and that number continues to rise. While therapies exist to reduce the amount of HIV in a patient's body and, in turn, reduce HIV symptoms, there remains no ...
Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...
(RTTNews) - Voyager Therapeutics, Inc. (VYGR), a developer of adeno-associated virus or AAV capsids, announced Tuesday a license option agreement, under which Novartis (NVS) will receive ...
Selecta Biosciences and Ginkgo Bioworks are extending their alliance to cover gene therapy delivery. Just months after disclosing a rare disease pact, the partners have unwrapped a second deal focused ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results